Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
Public ClinicalTrials.gov record NCT05426174. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
Study identification
- NCT ID
- NCT05426174
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Enrollment
- 233 participants
Conditions and interventions
Conditions
Interventions
- High Dose Quadrivalent Influenza Vaccine Biological
- mRNA NA vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2022
- Primary completion
- Jan 2, 2024
- Completion
- Jan 2, 2024
- Last update posted
- Sep 14, 2025
2022 – 2024
United States locations
- U.S. sites
- 6
- U.S. states
- 6
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AES - DRS - Optimal Research_Site 8400007 | Huntsville | Alabama | 35802 | — |
| Central Phoenix Medical Clinic, LLC_Site: 8400010 | Phoenix | Arizona | 85020 | — |
| Optimal Research San Diego, LLC_Site: 8400009 | San Diego | California | 92108 | — |
| AES - DRS - Optimal Research_Site 8400002 | Melbourne | Florida | 32934-8172 | — |
| AES - DRS - Optimal Research_Site 8400001 | Peoria | Illinois | 61614-4885 | — |
| Synexus Clinical Research_Site 8400003 | Cincinnati | Ohio | 45236 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05426174, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05426174 live on ClinicalTrials.gov.